Research programme: thrombin inhibitors - Abbott
Alternative Names: Thrombin inhibitors research programme - AbbottLatest Information Update: 24 Oct 2021
At a glance
- Originator Abbott Laboratories
- Class
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Deep vein thrombosis
Most Recent Events
- 24 Jan 2013 Discontinued - Phase-I for Deep vein thrombosis in Germany (PO)
- 12 Jul 2004 No development reported - Phase-I for Deep vein thrombosis in Germany (PO)
- 13 Mar 2001 BASF Pharma has been acquired by Abbott Laboratories